Cookies: Information & Consent

We have placed cookies on your device to help make this website better. Some of the cookies we use are essential for this site to work. We also use some non-essential cookies to collect information for making reports and to help us improve the site. You will find more detailled information in our Privacy Chart.

March 2020

Banook Group welcomes Turenne Santé as new investor, alongside the management

Funds obtained will enable the European leader in cardiac safety to continue its…
Read the full post
May 2018

Webinar : Advances in cardiovascular diagnostic devices for clinical trial

Tuesday, May 29th, 2018  6:00 PM CEST (Central European Time) UTC/GMT + 2…
Read the full post
April 2017

Event Participation 2017

Banook Group will attend the following exhibitions. Let’s meet there!
Read the full post
February 2017

Cardiabase by Banook Group opens subsidiary in Montreal, Canada

Group strengthens its presence in North American market, aiming for 30% growth in…
Read the full post
March 2015

Banook Group - New branding announcement

Cardiabase/Banook Central Imaging becomes Banook Group - New branding announcement.
Read the full post
March 2014

Webinar: Imaging anti-cancer treatment response at a preclinical and clinical stage

Use of imaging in oncology clinical trials is mainly based on morphological evaluation…
Read the full post
February 2017

Cardiabase by Banook Group opens subsidiary in Montreal, Canada

Group strengthens its presence in North American market, aiming for 30% growth in turnover


Nancy, France, February 21, 2017 - The Banook Group, global provider of cardiac safety, central imaging and endpoint adjudication services for clinical trials, today announces that it has opened a new subsidiary at the Neomed Institute, a center of excellence in clinical research, in Montreal, Canada.


The new subsidiary will strengthen the Banook Group’s presence in North America, which already accounts for 25% of its turnover. With this subsidiary the company is aiming for an average growth of 30% by 2018.


The North American market is an important focus for companies servicing clinical trials, such as the Banook Group, as the USA and Canada represent over 40%[1] of the CRO market size (based on the number of trials being conducted in each country/ region).


The launch of a Canadian subsidiary reflects the ongoing commitment of the Banook Group to maximizing value for its customers; providing superior support based on a “follow the sun” model (tasks are passed around daily between work sites to cover many time zones).


“We believe that our new subsidiary in Montreal will allow us to offer better adapted services and improved response time to the needs of our North American customers thanks to the proximity and our presence across several timezones,” said Pascal Voiriot, chairman of the Banook Group. “Our new location will also enable us to closely observe technology improvements, forge new partnerships and provide more opportunities to attend key industry events.”


“We are very pleased to welcome a new French based company to our facilities”, said Philippe Walker, PhD, general manager R&D & CSO. “The arrival of the Banook Group inside the Neomed Institute is a win-win situation, Neomed gets a robust service provider in clinical trials to add in the ecosystem and the Banook Group has access to our incredible know how on the north America biotechnology market.”


The Banook Group has offices in Nancy (France) and already has a long track record with numerous North American large pharma and biotech companies.


The company plans to attend several conferences in North America in 2017, including DIA in Chicago in June. The Banook Group also expects to set up partnerships with local specialized companies.


About the Banook Group

The Banook Group is one of the few international providers capable of supplying cardiac safety, central imaging and endpoint adjudication services to pharmaceutical groups, biotech companies, medical device manufacturers, CROs and nonprofit organizations.

Its mission is to help its clients develop the healthcare of tomorrow, using high quality, reliable and innovative solutions for all phases of clinical trials and ultimately to bring new solutions to market for the benefit of patients.

Its medical and regulatory expertise, quality-driven approach and team availability make the Banook Group a key player for clinical trial services.

Founded in 1999, the Banook Group is a non-listed family company. Financially solid and stable, the group operates on an international scale, maintaining offices at its headquarters in Nancy (France) and in Montreal (Quebec, Canada).

To learn more about the subsidiaries of the Banook Group (CardiaBase, Banook Central Imaging and Banook Inc.) please visit our website: 


About the NEOMED Institute

The NEOMED Institute is a not‐for‐profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favorable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint‐Laurent Campus, specializing in small molecule therapeutics, and the other, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.


The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.